XML 71 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Significant Accounting Policies - Schedule Of Impact Of Restatement On Certain Line Items And Balance Sheet (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]                    
Other asset impairments, restructuring and other items $ 57 $ 108 $ 110 $ 217 $ 31 $ 137 $ 718 [1] $ 512 [1] $ 341 [1]  
Operating income (loss) 344 (654) (13) (940) 424 (967) 433 [1] (2,197) [1] 1,716 [1]  
Income (loss) before income taxes 64 (923) (272) (1,185) 171 (1,178) (624) [1],[2] (3,163) [1],[2] 658 [1],[2]  
Income taxes (benefit) (12) (16) (19) 149 107 (900) (7) [2] (643) [2] 211 [2]  
Net income (loss) 78 (905) (253) (1,333) 63 (278) (615) (2,499) 456  
Net income (loss) attributable to Teva $ 70 $ (871) $ (220) $ (1,301) $ 61 $ (251) $ (559) $ (2,446) $ 417  
Earnings (loss) per share attributable to ordinary shareholders:                    
Basic $ 0.06 $ (0.78) $ (0.2) $ (1.17) $ 0.05 $ (0.23) $ (0.5) $ (2.2) $ 0.38  
Diluted $ 0.06 $ (0.78) $ (0.2) $ (1.17) $ 0.05 $ (0.23) $ (0.5) $ (2.2) $ 0.38  
Deferred income taxes $ 1,755 $ 1,583 $ 1,577 $ 1,458 $ 1,546 $ 1,595 $ 1,812 $ 1,458    
Total assets 42,095 43,100 43,461 44,011 44,252 45,932 43,479 44,011    
Other taxes and long-term liabilities 3,950 4,094 3,982 3,945 3,859 3,860 4,019 3,945    
Total long-term liabilities 23,314 23,664 24,546 23,944 23,213 25,125 23,106 23,944    
Total liabilities 34,708 35,508 34,957 35,413 34,747 36,121 35,353 35,413    
Teva shareholders' equity:                    
Accumulated deficit (13,995) (14,066) (13,194) (12,975) (11,673) (11,734) (13,534) (12,975)    
Total equity 7,387 7,592 8,504 8,598 9,506 9,810 8,126 8,598 $ 11,244 $ 11,061
Total liabilities and equity 42,095 43,100 43,461 44,011 44,252 45,932 $ 43,479 44,011    
As previously reported [Member]                    
Error Corrections and Prior Period Adjustments Restatement [Line Items]                    
Other asset impairments, restructuring and other items 46 100 96 132 36 118   414    
Operating income (loss) 355 (646) 2 (855) 419 (949)   (2,099)    
Income (loss) before income taxes 75 (914) (258) (1,100) 166 (1,160)   (3,065)    
Income taxes (benefit) (12) (16) (19) 154 107 (900)   (638)    
Net income (loss) 88 (898) (238) (1,254) 58 (259)   (2,406)    
Net income (loss) attributable to Teva $ 80 $ (863) $ (205) $ (1,221) $ 56 $ (232)   $ (2,353)    
Earnings (loss) per share attributable to ordinary shareholders:                    
Basic $ 0.07 $ (0.77) $ (0.18) $ (1.1) $ 0.05 $ (0.21)   $ (2.12)    
Diluted $ 0.07 $ (0.77) $ (0.18) $ (1.1) $ 0.05 $ (0.21)   $ (2.12)    
Deferred income taxes $ 1,748 $ 1,578 $ 1,572 $ 1,453 $ 1,546 $ 1,595   $ 1,453    
Total assets 42,088 43,095 43,456 44,006 44,252 45,932   44,006    
Other taxes and long-term liabilities 3,818 3,973 3,869 3,847 3,846 3,842   3,847    
Total long-term liabilities 23,182 23,543 24,433 23,846 23,200 25,107   23,846    
Total liabilities 34,576 35,387 34,844 35,315 34,734 36,103   35,315    
Teva shareholders' equity:                    
Accumulated deficit (13,870) (13,950) (13,086) (12,882) (11,660) (11,716)   (12,882)    
Total equity 7,512 7,708 8,612 8,691 9,519 9,828   8,691    
Total liabilities and equity 42,088 43,095 43,456 44,006 44,252 45,932   44,006    
Adjustment [Member]                    
Error Corrections and Prior Period Adjustments Restatement [Line Items]                    
Other asset impairments, restructuring and other items 11 8 15 85 (5) 18   98    
Operating income (loss) (11) (8) (15) (85) 5 (18)   (98)    
Income (loss) before income taxes (11) (8) (15) (85) 5 (18)   (98)    
Income taxes (benefit)       (5)       (5)    
Net income (loss) (11) (8) (15) (80) 5 (18)   (93)    
Net income (loss) attributable to Teva $ (11) $ (8) $ (15) $ (80) $ 5 $ (18)   $ (93)    
Earnings (loss) per share attributable to ordinary shareholders:                    
Basic $ (0.01) $ (0.01) $ (0.02) $ (0.07) $ 0 $ (0.02)   $ (0.08)    
Diluted $ (0.01) $ (0.01) $ (0.02) $ (0.07) $ 0 $ (0.02)   $ (0.08)    
Deferred income taxes $ 7 $ 5 $ 5 $ 5       $ 5    
Total assets 7 5 5 5       5    
Other taxes and long-term liabilities 132 121 113 98 $ 13 $ 18   98    
Total long-term liabilities 132 121 113 98 13 18   98    
Total liabilities 132 121 113 98 13 18   98    
Teva shareholders' equity:                    
Accumulated deficit (125) (116) (108) (93) (13) (18)   (93)    
Total equity (125) (116) (108) (93) (13) (18)   (93)    
Total liabilities and equity $ 7 $ 5 $ 5 $ 5 $ 0 $ 0   $ 5    
[1] The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b.
[2] The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.